SARS-CoV Pathogenesis Is Regulated by a STAT1 Dependent but a Type I, II and III Interferon Receptor Independent Mechanism
Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly. The virus-host interactions that governed development of these acute end stage lung diseases and death are unknown. To address this question, we evaluated the role of innate immune signaling in protection from human (Urbani) and a recombinant mouse adapted SARS-CoV, designated rMA15. In contrast to most models of viral pathogenesis, infection of type I, type II or type III interferon knockout mice (129 background) with either Urbani or MA15 viruses resulted in clinical disease outcomes, including transient weight loss, denuding bronchiolitis and alveolar inflammation and recovery, identical to that seen in infection of wildtype mice. This suggests that type I, II and III interferon signaling play minor roles in regulating SARS pathogenesis in mouse models. In contrast, infection of STAT1−/− mice resulted in severe disease, high virus titer, extensive pulmonary lesions and 100% mortality by day 9 and 30 post-infection with rMA15 or Urbani viruses, respectively. Non-lethal in BALB/c mice, Urbani SARS-CoV infection in STAT1−/− mice caused disseminated infection involving the liver, spleen and other tissues after day 9. These findings demonstrated that SARS-CoV pathogenesis is regulated by a STAT1 dependent but type I, II and III interferon receptor independent, mechanism. In contrast to a well documented role in innate immunity, we propose that STAT1 also protects mice via its role as an antagonist of unrestrained cell proliferation.
Vyšlo v časopise:
SARS-CoV Pathogenesis Is Regulated by a STAT1 Dependent but a Type I, II and III Interferon Receptor Independent Mechanism. PLoS Pathog 6(4): e32767. doi:10.1371/journal.ppat.1000849
Kategorie:
Research Article
prolekare.web.journal.doi_sk:
https://doi.org/10.1371/journal.ppat.1000849
Souhrn
Severe acute respiratory syndrome coronavirus (SARS-CoV) infection often caused severe end stage lung disease and organizing phase diffuse alveolar damage, especially in the elderly. The virus-host interactions that governed development of these acute end stage lung diseases and death are unknown. To address this question, we evaluated the role of innate immune signaling in protection from human (Urbani) and a recombinant mouse adapted SARS-CoV, designated rMA15. In contrast to most models of viral pathogenesis, infection of type I, type II or type III interferon knockout mice (129 background) with either Urbani or MA15 viruses resulted in clinical disease outcomes, including transient weight loss, denuding bronchiolitis and alveolar inflammation and recovery, identical to that seen in infection of wildtype mice. This suggests that type I, II and III interferon signaling play minor roles in regulating SARS pathogenesis in mouse models. In contrast, infection of STAT1−/− mice resulted in severe disease, high virus titer, extensive pulmonary lesions and 100% mortality by day 9 and 30 post-infection with rMA15 or Urbani viruses, respectively. Non-lethal in BALB/c mice, Urbani SARS-CoV infection in STAT1−/− mice caused disseminated infection involving the liver, spleen and other tissues after day 9. These findings demonstrated that SARS-CoV pathogenesis is regulated by a STAT1 dependent but type I, II and III interferon receptor independent, mechanism. In contrast to a well documented role in innate immunity, we propose that STAT1 also protects mice via its role as an antagonist of unrestrained cell proliferation.
Zdroje
1. DonnellyCA
GhaniAC
LeungGM
HedleyAJ
FraserC
2003 Epidemiological determinants of spread of causal agent of severe acute respiratory syndrome in Hong Kong. Lancet 361 1761 1766
2. DrostenC
GuntherS
PreiserW
van der WerfS
BrodtHR
2003 Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 348 1967 1976
3. LevyDE
Garcia-SastreA
2001 The virus battles: IFN induction of the antiviral state and mechanisms of viral evasion. Cytokine Growth Factor Rev 12 143 156
4. SethRB
SunL
ChenZJ
2006 Antiviral innate immunity pathways. Cell Res 16 141 147
5. TakaokaA
YanaiH
2006 Interferon signalling network in innate defence. Cell Microbiol 8 907 922
6. RymanKD
WhiteLJ
JohnstonRE
KlimstraWB
2002 Effects of PKR/RNase L-dependent and alternative antiviral pathways on alphavirus replication and pathogenesis. Viral Immunol 15 53 76
7. DurbinJE
JohnsonTR
DurbinRK
MertzSE
MorottiRA
2002 The role of IFN in respiratory syncytial virus pathogenesis. J Immunol 168 2944 2952
8. JohnsonTR
MertzSE
GitibanN
HammondS
LegalloR
2005 Role for innate IFNs in determining respiratory syncytial virus immunopathology. J Immunol 174 7234 7241
9. KellerBC
FredericksenBL
SamuelMA
MockRE
MasonPW
2006 Resistance to alpha/beta interferon is a determinant of West Nile virus replication fitness and virulence. J Virol 80 9424 9434
10. DurbinJE
HackenmillerR
SimonMC
LevyDE
1996 Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease. Cell 84 443 450
11. BrayM
2001 The role of the Type I interferon response in the resistance of mice to filovirus infection. J Gen Virol 82 1365 1373
12. DurbinJE
Fernandez-SesmaA
LeeCK
RaoTD
FreyAB
2000 Type I IFN modulates innate and specific antiviral immunity. J Immunol 164 4220 4228
13. BaslerCF
WangX
MuhlbergerE
VolchkovV
ParagasJ
2000 The Ebola virus VP35 protein functions as a type I IFN antagonist. Proc Natl Acad Sci U S A 97 12289 12294
14. ReidSP
LeungLW
HartmanAL
MartinezO
ShawML
2006 Ebola virus VP24 binds karyopherin alpha1 and blocks STAT1 nuclear accumulation. J Virol 80 5156 5167
15. SalvatoreM
BaslerCF
ParisienJP
HorvathCM
BourmakinaS
2002 Effects of influenza A virus NS1 protein on protein expression: the NS1 protein enhances translation and is not required for shutoff of host protein synthesis. J Virol 76 1206 1212
16. YuanW
KrugRM
2001 Influenza B virus NS1 protein inhibits conjugation of the interferon (IFN)-induced ubiquitin-like ISG15 protein. Embo J 20 362 371
17. RodriguezJJ
ParisienJP
HorvathCM
2002 Nipah virus V protein evades alpha and gamma interferons by preventing STAT1 and STAT2 activation and nuclear accumulation. J Virol 76 11476 11483
18. FriemanM
YountB
HeiseM
Kopecky-BrombergSA
PaleseP
2007 Severe acute respiratory syndrome coronavirus ORF6 antagonizes STAT1 function by sequestering nuclear import factors on the rough endoplasmic reticulum/Golgi membrane. J Virol 81 9812 9824
19. Kopecky-BrombergSA
Martinez-SobridoL
FriemanM
BaricRA
PaleseP
2007 Severe acute respiratory syndrome coronavirus open reading frame (ORF) 3b, ORF 6, and nucleocapsid proteins function as interferon antagonists. J Virol 81 548 557
20. WatheletMG
OrrM
FriemanMB
BaricRS
2007 Severe acute respiratory syndrome coronavirus evades antiviral signaling: role of nsp1 and rational design of an attenuated strain. J Virol 81 11620 11633
21. ZhaoJ
FalconA
ZhouH
NetlandJ
EnjuanesL
2009 Severe acute respiratory syndrome coronavirus protein 6 is required for optimal replication. J Virol 83 2368 2373
22. CameronMJ
RanL
XuL
DaneshA
Bermejo-MartinJF
2007 Interferon-mediated immunopathological events are associated with atypical innate and adaptive immune responses in patients with severe acute respiratory syndrome. J Virol 81 8692 8706
23. RockxB
BaasT
ZornetzerGA
HaagmansB
SheahanT
2009 Early Upregulation of ARDS Associated Cytokines Promote Lethal Disease in an Aged Mouse Model of SARS-CoV Infection. J Virol
24. BaasT
RobertsA
TealTH
VogelL
ChenJ
2008 Genomic analysis reveals age-dependent innate immune responses to severe acute respiratory syndrome coronavirus. J Virol 82 9465 9476
25. HaynesLM
MooreDD
Kurt-JonesEA
FinbergRW
AndersonLJ
2001 Involvement of toll-like receptor 4 in innate immunity to respiratory syncytial virus. J Virol 75 10730 10737
26. SheahanT
MorrisonTE
FunkhouserW
UematsuS
AkiraS
2008 MyD88 is required for protection from lethal infection with a mouse-adapted SARS-CoV. PLoS Pathog 4 e1000240 doi:10.1371/journal.ppat.1000240
27. HallerO
ArnheiterH
GresserI
LindenmannJ
1981 Virus-specific interferon action. Protection of newborn Mx carriers against lethal infection with influenza virus. J Exp Med 154 199 203
28. GlassWG
SubbaraoK
MurphyB
MurphyPM
2004 Mechanisms of host defense following severe acute respiratory syndrome-coronavirus (SARS-CoV) pulmonary infection of mice. J Immunol 173 4030 4039
29. HoganRJ
GaoG
RoweT
BellP
FliederD
2004 Resolution of primary severe acute respiratory syndrome-associated coronavirus infection requires Stat1. J Virol 78 11416 11421
30. RobertsA
DemingD
PaddockCD
ChengA
YountB
2007 A Mouse-Adapted SARS-Coronavirus Causes Disease and Mortality in BALB/c Mice. PLoS Pathog 3 e5 doi:10.1371/journal.ppat.0030005
31. LoAW
TangNL
ToKF
2006 How the SARS coronavirus causes disease: host or organism? J Pathol 208 142 151
32. HwangDM
ChamberlainDW
PoutanenSM
LowDE
AsaSL
2005 Pulmonary pathology of severe acute respiratory syndrome in Toronto. Mod Pathol 18 1 10
33. PaulNS
RobertsH
ButanyJ
ChungT
GoldW
2004 Radiologic pattern of disease in patients with severe acute respiratory syndrome: the Toronto experience. Radiographics 24 553 563
34. KetaiL
PaulNS
WongKT
2006 Radiology of severe acute respiratory syndrome (SARS): the emerging pathologic-radiologic correlates of an emerging disease. J Thorac Imaging 21 276 283
35. RobertsA
PaddockC
VogelL
ButlerE
ZakiS
2005 Aged BALB/c mice as a model for increased severity of severe acute respiratory syndrome in elderly humans. J Virol 79 5833 5838
36. SubbaraoK
McAuliffeJ
VogelL
FahleG
FischerS
2004 Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice. J Virol 78 3572 3577
37. KotenkoSV
GallagherG
BaurinVV
Lewis-AntesA
ShenM
2003 IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 4 69 77
38. SchindlerC
DarnellJEJr
1995 Transcriptional responses to polypeptide ligands: the JAK-STAT pathway. Annu Rev Biochem 64 621 651
39. KoernerI
KochsG
KalinkeU
WeissS
StaeheliP
2007 Protective role of beta interferon in host defense against influenza A virus. J Virol 81 2025 2030
40. GerlachN
SchimmerS
WeissS
KalinkeU
DittmerU
2006 Effects of type I interferons on Friend retrovirus infection. J Virol 80 3438 3444
41. KussSK
EtheredgeCA
PfeifferJK
2008 Multiple host barriers restrict poliovirus trafficking in mice. PLoS Pathog 4 e1000082 doi:10.1371/journal.ppat.1000082
42. KatzeMG
HeY
GaleMJr
2002 Viruses and interferon: a fight for supremacy. Nat Rev Immunol 2 675 687
43. WaltersDM
Antao-MenezesA
IngramJL
RiceAB
NyskaA
2005 Susceptibility of signal transducer and activator of transcription-1-deficient mice to pulmonary fibrogenesis. Am J Pathol 167 1221 1229
44. Antao-MenezesA
TurpinEA
BostPC
Ryman-RasmussenJP
BonnerJC
2008 STAT-1 signaling in human lung fibroblasts is induced by vanadium pentoxide through an IFN-beta autocrine loop. J Immunol 180 4200 4207
45. BrombergJ
DarnellJEJr
2000 The role of STATs in transcriptional control and their impact on cellular function. Oncogene 19 2468 2473
46. FrankDA
1999 STAT signaling in the pathogenesis and treatment of cancer. Mol Med 5 432 456
47. KlampferL
2006 Signal transducers and activators of transcription (STATs): Novel targets of chemopreventive and chemotherapeutic drugs. Curr Cancer Drug Targets 6 107 121
48. LevitzkiA
MishaniE
2006 Tyrphostins and other tyrosine kinase inhibitors. Annu Rev Biochem 75 93 109
49. YoonP
KeylockKT
HartmanME
FreundGG
WoodsJA
2004 Macrophage hypo-responsiveness to interferon-gamma in aged mice is associated with impaired signaling through Jak-STAT. Mech Ageing Dev 125 137 143
50. LauYL
PeirisJS
2005 Pathogenesis of severe acute respiratory syndrome. Curr Opin Immunol 17 404 410
51. FriemanM
RatiaK
JohnstonRE
MesecarAD
BaricRS
2009 Severe acute respiratory syndrome coronavirus papain-like protease ubiquitin-like domain and catalytic domain regulate antagonism of IRF3 and NF-kappaB signaling. J Virol 83 6689 6705
52. NichollsJM
ButanyJ
PoonLL
ChanKH
BehSL
2006 Time course and cellular localization of SARS-CoV nucleoprotein and RNA in lungs from fatal cases of SARS. PLoS Med 3 e27 doi:10.1371/journal.pmed.0030027
53. Chan-YeungM
XuRH
2003 SARS: epidemiology. Respirology 8 Suppl S9 14
Štítky
Hygiena a epidemiológia Infekčné lekárstvo LaboratóriumČlánok vyšiel v časopise
PLOS Pathogens
2010 Číslo 4
- Parazitičtí červi v terapii Crohnovy choroby a dalších zánětlivých autoimunitních onemocnění
- Očkování proti virové hemoragické horečce Ebola experimentální vakcínou rVSVDG-ZEBOV-GP
- Koronavirus hýbe světem: Víte jak se chránit a jak postupovat v případě podezření?
Najčítanejšie v tomto čísle
- The Effect of Vaccination on the Evolution and Population Dynamics of Avian Paramyxovirus-1
- Reconstitution of SARS-Coronavirus mRNA Cap Methylation
- Deficiencies in Jasmonate-Mediated Plant Defense Reveal Quantitative Variation in Pathogenesis
- A Timescale for Evolution, Population Expansion, and Spatial Spread of an Emerging Clone of Methicillin-Resistant